TrialClinIQ | $150,000 | (Apr 29, 2026)
Lighthouse Pharmaceuticals | $12,000,000 | (Apr 29, 2026)
Windmill(US) | $12,000,000 | (Apr 29, 2026)
Certified by Founder
Lodge
Tenvie Therapeutics
start up
United States
- South San Francisco, California
- 09/01/2025
- Unknown
- $200,000,000
Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function.
- Industry Biotechnology Research
- Website https://tenvie.com/
- LinkedIn https://www.linkedin.com/company/tenvie-therapeutics/
IC Realtime | $2,000,000 | (Apr 29, 2026)
Golden Child | $37,000,000 | (Apr 29, 2026)
Hypervision Surgical | $22,962,410 | (Apr 29, 2026)
dehaze | $3,746,192 | (Apr 29, 2026)
Clarasight | $11,500,000 | (Apr 29, 2026)
Liquid Instruments | $50,000,000 | (Apr 29, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)